11 analysts have expressed a variety of opinions on Apellis Pharmaceuticals (NASDAQ:APLS) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 2 | 0 | 2 | 0 | 0 |
| 2M Ago | 2 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $30.91, along with a high estimate of $48.00 and a low estimate of $18.00. Experiencing a 6.62% decline, the current average is now lower than the previous average price target of $33.10.
Interpreting Analyst Ratings: A Closer Look
The perception of Apellis Pharmaceuticals by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Graig Suvannavejh | Mizuho | Raises | Neutral | $20.00 | $19.00 |
| Yigal Nochomovitz | Citigroup | Lowers | Buy | $44.00 | $45.00 |
| Lisa Walter | RBC Capital | Lowers | Sector Perform | $21.00 | $22.00 |
| Laura Chico | Wedbush | Lowers | Neutral | $18.00 | $20.00 |
| Douglas Tsao | HC Wainwright & Co. | Raises | Buy | $48.00 | $45.00 |
| Eliana Merle | Barclays | Announces | Equal-Weight | $24.00 | - |
| Tazeen Ahmad | B of A Securities | Maintains | Buy | $28.00 | $28.00 |
| Derek Archila | Wells Fargo | Lowers | Overweight | $26.00 | $29.00 |
| Steve Seedhouse | Cantor Fitzgerald | Lowers | Overweight | $35.00 | $39.00 |
| Joseph Stringer | Needham | Lowers | Buy | $28.00 | $29.00 |
| Annabel Samimy | Stifel | Lowers | Buy | $48.00 | $55.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Apellis Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Apellis Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Apellis Pharmaceuticals's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Apellis Pharmaceuticals analyst ratings.
Unveiling the Story Behind Apellis Pharmaceuticals
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. Currently it has two marketed drugs that target C3, the central protein in the complement cascade: SYFOVRE (pegcetacoplan injection) and EMPAVELI (pegcetacoplan).
Key Indicators: Apellis Pharmaceuticals's Financial Health
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Challenges: Apellis Pharmaceuticals's revenue growth over 3M faced difficulties. As of 31 December, 2025, the company experienced a decline of approximately -5.94%. This indicates a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Apellis Pharmaceuticals's net margin excels beyond industry benchmarks, reaching -29.49%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -15.29%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -5.53%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio surpasses industry norms, standing at 1.28. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
The Basics of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Login to comment